Last reviewed · How we verify
FLAG-IDA
FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells.
FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells. Used for Acute myeloid leukemia (AML), relapsed or refractory, Acute lymphoblastic leukemia (ALL), relapsed or refractory.
At a glance
| Generic name | FLAG-IDA |
|---|---|
| Also known as | Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin |
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Drug class | Combination chemotherapy regimen |
| Target | DNA synthesis machinery; Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FLAG-IDA combines fludarabine (a purine analog), cytarabine (a pyrimidine analog), and idarubicin (a topoisomerase II inhibitor) to target leukemic cells through multiple mechanisms. Fludarabine and cytarabine interfere with DNA synthesis, while idarubicin intercalates DNA and inhibits topoisomerase II, leading to cell death. This combination is particularly effective in hematologic malignancies with high proliferation rates.
Approved indications
- Acute myeloid leukemia (AML), relapsed or refractory
- Acute lymphoblastic leukemia (ALL), relapsed or refractory
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Mucositis
- Nausea and vomiting
- Diarrhea
- Cardiotoxicity
- Hepatotoxicity
Key clinical trials
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (PHASE1)
- Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer (PHASE2)
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |